Eris Lifesciences — 360° view

Eris Lifesciences, a company in the Pharmaceuticals industry, reported revenue of ₹892 crore and net profit of ₹187 crore for the September 2026 quarter.

Eris Lifesciences (NSE: ERIS) closed at ₹1,317.20 on 20 Nov 2026, down 21.1% over the past year. Its market capitalisation is ₹18,275 crore and it trades at 24.5 times earnings.

Share price
₹1,317.20 (20 Nov 2026)
Market cap
₹18,275 Cr (20 Nov 2026)
P/E
24.47 (20 Nov 2026)
Revenue
₹892 Cr (September 2026 quarter)
Net profit
₹187 Cr (September 2026 quarter)
ROCE
14.1% (FY26)
ROE
18.7% (FY26)
Book value
₹299 (FY26)
Dividend yield
0.55% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,740.00 / ₹1,069.00 (20 Nov 2026)
1-year return
-21.1% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: ERIS

ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.